NZ335081A - Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer - Google Patents

Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer

Info

Publication number
NZ335081A
NZ335081A NZ335081A NZ33508197A NZ335081A NZ 335081 A NZ335081 A NZ 335081A NZ 335081 A NZ335081 A NZ 335081A NZ 33508197 A NZ33508197 A NZ 33508197A NZ 335081 A NZ335081 A NZ 335081A
Authority
NZ
New Zealand
Prior art keywords
oligopeptide
treatment
amino acid
prostate cancer
linker
Prior art date
Application number
NZ335081A
Inventor
Victor M Garsky
Dong-Mei Feng
Deborah Defeo-Jones
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Priority claimed from PCT/US1997/019225 external-priority patent/WO1998018493A2/en
Publication of NZ335081A publication Critical patent/NZ335081A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

A conjugate comprises a cytotoxic agent attached to an oligopeptide comprising a sequence of amino acids that is selectively proteolytically cleaved by free prostate specific antigen or an optical isomer or pharmaceutically acceptable salt thereof. The means of attachment between the cytotoxic agent and the oligopeptide is a covalent bond or through a chemical linker. The sequence of amino acids comprises at least one cyclic amino acid having a hydrophilic substituent The conjugate is useful for the treatment of prostate cancer.
NZ335081A 1996-10-30 1997-10-27 Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer NZ335081A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer
PCT/US1997/019225 WO1998018493A2 (en) 1996-10-30 1997-10-27 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
NZ335081A true NZ335081A (en) 2001-01-26

Family

ID=27268641

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335081A NZ335081A (en) 1996-10-30 1997-10-27 Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer

Country Status (1)

Country Link
NZ (1) NZ335081A (en)

Similar Documents

Publication Publication Date Title
JP6290166B2 (en) Preparation of injectable pharmaceutical preparations
JP5392956B2 (en) Carrier-drug complex
AU663167B2 (en) Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
HUP0000651A2 (en) Conjugates useful in the treatment of prostate cancer
DK434188A (en) ANTIBODY ENZYMY CONJUGATES IN COMBINATION WITH PROLAGENTS FOR THE SUPPLY OF CYTOTOXIC AGENTS FOR TUMOR CELLS
HUT75058A (en) Amplification of the vitamin b12 uptake system using polymers
PT1146861E (en) HYDROGEL PARTICLE FORMULATIONS
AU3963889A (en) Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
EP0438497A4 (en) Vasopermeability-enhancing conjugates
CA1330378C (en) Amine derivatives of folic acid analogs
NO993866L (en) Medication for lymphatic tumors
US20020155999A1 (en) Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
AR016427A1 (en) USEFUL CONJUGATES FOR THE TREATMENT OF PROSSTATA CANCER, AND A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM.
NZ335081A (en) Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer
EP0485749A2 (en) Chemical modification of antibodies for creating of immunoconjugates
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
Hoes et al. Design of soluble conjugates of biodegradable polymeric carriers and adriamycin
IL117564A0 (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
EA200100311A1 (en) Bifunctional antibodies and their application for targeted delivery of antitumor agents
RU94045008A (en) Method of blood-brain barrier overcoming
ITMI931082A1 (en) CONJUGATES OF ANTIVIRAL DRUGS WITH HEPATOTROPIC ACTIVITY, RELATED VEHICULANTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2458872A1 (en) Human ubiquitin-conjugating enzyme
TH35575A3 (en) Formula
MY103598A (en) Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)